Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.

Bamberger, Florian; König, Inke R; Gola, Damian; Zillikens, Detlef; Sadik, Christian D

Bamberger, Florian; König, Inke R; Gola, Damian; Zillikens, Detlef; Sadik, Christian D.

Affiliation

Bamberger F; Department of Dermatology, Allergy, and Venereology, Lübeck, Germany.
König IR; Institute of Medical Biometry and Statistics (IMBS), Lübeck, Germany.
Gola D; Center for Research on Inflammation of the Skin (CRIS), University of Lübeck, Lübeck, Germany.
Zillikens D; Institute of Medical Biometry and Statistics (IMBS), Lübeck, Germany.
Sadik CD; Department of Dermatology, Allergy, and Venereology, Lübeck, Germany.

Front Immunol ; 14: 1180150, 2023.

Article in En | MEDLINE | ID: mdl-37143653

Subject(s)
Key words

B cell depletion; autoantibodies; mucous membrane pemphigoid; mucous membrane pemphigoid disease index; pemphigoid disease; retrospective study; rituximab; side-effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Pemphigoid, Benign Mucous Membrane / Pemphigoid, Bullous Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Alemania Country of publication: Suiza

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google